Aptose Biosciences Inc. (APTO)
NASDAQ: APTO
· Real-Time Price · USD
1.71
0.00 (0.00%)
At close: Apr 01, 2025, 3:59 PM
Aptose Biosciences Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | 955.27K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | 117.97K | 108.51K | 356.1K | 109.59K | 115.5K | 131.01K | 100.15K | 133.08K | 139.8K | 147.79K | 162.45K | 153.94K | 150.71K | 153.13K |
Gross Profit | n/a | n/a | n/a | -117.97K | -108.51K | 599.17K | -109.59K | -115.5K | -131.01K | -100.15K | -133.08K | -139.8K | -147.79K | -162.45K | -153.94K | -150.71K | -153.13K |
Operating Income | -5.46M | -2.19M | -6.96M | -7.34M | -9.76M | -12.13M | -11.45M | -14.45M | -14.1M | -10.4M | -10.03M | -10.67M | -11.5M | -24.35M | -11.36M | -13.49M | -16.25M |
Interest Income | n/a | 131K | 12K | 93K | 121K | 171K | 232K | 326K | 422K | 401K | 254K | 111K | 22K | 22K | 22K | 23K | 27K |
Pretax Income | -5.54M | -1.58M | -6.95M | -7.25M | -9.64M | -11.96M | -11.45M | -14.13M | -13.68M | -10M | -9.78M | -10.56M | -11.48M | -24.32M | -11.33M | -13.47M | -16.23M |
Net Income | -5.54M | -1.58M | -6.95M | -7.25M | -9.64M | -11.96M | -11.45M | -14.13M | -13.68M | -10M | -9.78M | -10.56M | -11.48M | -24.32M | -11.33M | -13.47M | -16.23M |
Selling & General & Admin | 3.09M | 2.64M | 2.26M | 2.93M | 3.31M | 3M | 3.42M | 3.87M | 5.29M | 3.61M | 3.45M | 3.33M | 4.11M | 4.11M | 3.64M | 3.66M | 8.02M |
Research & Development | 2.36M | -457K | 4.7M | 4.41M | 6.41M | 9.12M | 8.26M | 10.58M | 8.81M | 6.78M | 6.58M | 7.34M | 7.39M | 20.21M | 7.72M | 9.83M | 8.23M |
Other Expenses | 3K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 18K | n/a | n/a | n/a | 34K | n/a | n/a | n/a |
Operating Expenses | 5.46M | 2.19M | 6.96M | 7.34M | 9.76M | 12.13M | 11.68M | 14.45M | 14.1M | 10.4M | 10.03M | 10.67M | 11.5M | 24.35M | 11.36M | 13.49M | 16.25M |
Interest Expense | 84K | 207K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 12K | n/a | -18K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 5.46M | 2.19M | 6.96M | 7.34M | 9.76M | 12.13M | 11.68M | 14.45M | 14.1M | 10.4M | 10.03M | 10.67M | 11.5M | 24.35M | 11.36M | 13.49M | 16.25M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 2.13M | 5.6M | 5.6M | 5.6M | 5.6M | 6.63M | 6.5M | 6.23M | 6.17M | 6.16M | 6.15M | 6.15M | 5.94M | 5.94M | 5.94M | 5.94M | 5.94M |
Shares Outstanding (Diluted) | 21.26K | 950.45K | 950.45K | 558.5K | 437.77K | 1.89M | 1.89M | 1.89M | 1.89M | 1.89M | 1.89M | 1.89M | 1.89M | 1.89M | 1.89M | 1.89M | 1.89M |
EPS (Basic) | -2.61 | -0.28 | -1.24 | -1.3 | -1.72 | -1.8 | -1.76 | -2.27 | -2.22 | -1.62 | -1.59 | -1.72 | -1.93 | -4.1 | -1.91 | -2.27 | -2.73 |
EPS (Diluted) | -260.69 | -1.67 | -7.32 | -12.98 | -22.02 | -6.32 | -6.05 | -7.47 | -7.23 | -5.29 | -5.17 | -5.59 | -6.07 | -12.86 | -5.99 | -7.12 | -8.58 |
EBITDA | -5.36M | -1.06M | -6.96M | -7.34M | -9.65M | -12.02M | -11.66M | -14.43M | -14.07M | -10.3M | -10M | -10.64M | -11.47M | -24.3M | -11.32M | -13.45M | -16.2M |
EBIT | -5.46M | -1.15M | -6.96M | -7.34M | -9.76M | -12.13M | -11.68M | -14.45M | -14.1M | -10.4M | -10.03M | -10.67M | -11.5M | -24.35M | -11.36M | -13.49M | -16.25M |
Depreciation & Amortization | n/a | -215K | 4K | 102K | 109K | 113.04K | 109.59K | 114K | 131K | 100K | 141K | 139.8K | 146K | 162.45K | 153.94K | 150.71K | 152K |